Clinical Trial Results:
Phase II study of irinotecan weekly in patients with locally advanced or metastatic HER2-negative breast cancer and increased cancer cell copy number of the topoisomerase 1 gene (TOP1)”
Summary
|
|
EudraCT number |
2012-002348-26 |
Trial protocol |
DK |
Global end of trial date |
05 Jul 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Nov 2019
|
First version publication date |
27 Nov 2019
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
MA1214
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Danish Breast Cancer Group (DBCG)
|
||
Sponsor organisation address |
Blegdamsvej 9, Copenhagen, Denmark, 2100
|
||
Public contact |
Department of Oncology, Herlev Hospital, 0045 38686472, iben.kumler@regionh.dk
|
||
Scientific contact |
Department of Oncology, Herlev Hospital, 0045 38686472, iben.kumler@regionh.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
12 Aug 2016
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
05 Jul 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
05 Jul 2016
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
Clinical benefit rate defined as the fraction of patients with stable disease >= 4 months, complete or partial response according to RECIST 1.1
|
||
Protection of trial subjects |
Eligibility criteria, standard safety monitoring
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Oct 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 9
|
||
Worldwide total number of subjects |
9
|
||
EEA total number of subjects |
9
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
5
|
||
From 65 to 84 years |
4
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
Recruitment was open at 6 sites in Denmark from October 2012 til July 2016. Patient were recruited from the pool of patients participating in a pre-screening protocol (not part of this trial) that analyses the copy number of topoisomerase 1 gene in patients with metastatic breast cancer. | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
Patients with metastatic breast cancer, negative for Her2 and increased copy number of topoisomerase 1 gene. Measurable disease according to RECIST 1.1, Max 3 or 4 (after an amendment) lines of chemotherapy for advanced or metastatic disease | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
Overall trial (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Not applicable
|
||||||||||||
Blinding used |
Not blinded | ||||||||||||
Arms
|
|||||||||||||
Arm title
|
Study treatment | ||||||||||||
Arm description |
Irinotecan | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Irinotecan
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Concentrate for solution for infusion
|
||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||
Dosage and administration details |
75 mg/m2 given weekly for 4 weeks followed by 2 weeks without administration. In case of non-PD this treatment was repeated every 6 weeks.
|
||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
|||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Study treatment
|
||
Reporting group description |
Irinotecan |
|
|||||||||
End point title |
Clinical Benefit Rate [1] | ||||||||
End point description |
Patients with SD >= 4 months, PR or CR
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
Tumor assessments were done every 6th week
|
||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analyses performed due to low number of patients |
|||||||||
|
|||||||||
Notes [2] - 2 patients were not evaluable |
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From treatment start to 28 days after last treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
NCI-CTCAE | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
4.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Study treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Irinotecan | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
22 Aug 2013 |
Inclusion criteria amendment from maximum of previously 3 lines of treatment for advanced of metastatic disease allowed to maximum of previously 4 lines of treatment for advanced of metastatic disease allowed |
||
03 Mar 2014 |
Starting dose of Irinotecan reduced from 100 mg/m2 to 75 mg/m2 |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
slow recruitment, Adequate patient number not reached at premature end of trial | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/31196001 |